Drug intelligence / Profile preview

recombinant type I herpes simplex virus R130 injection (Vero cells)

Development stage: Unknown
Lead developer: Shanghai Yunying Medical Technology
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intraperitoneal, Intratumoral

Overview

Recombinant type I herpes simplex virus R130 injection (Vero cells) is a third-generation recombinant oncolytic herpes simplex virus type 1 (oHSV-1) developed by Shanghai Yunying Medical Technology. Engineered to selectively replicate in and lyse tumor cells, R130 is armed with multiple immunomodulatory transgenes, including an anti-CD3 single-chain variable fragment (scFv), CD86, and PD-1, alongside the HSV-2 US11 gene to enhance viral replication. This multi-pronged design enables R130 to directly destroy cancer cells while simultaneously recruiting and activating T cells within the tumor microenvironment, reversing T-cell exhaustion and promoting a robust systemic anti-tumor immune response. R130 is currently in Early Phase 1 clinical development in China for the treatment of advanced solid tumors, including bone and soft tissue tumors.

Other names: Recombinant Herpes Simplex Virus Type I R130 Injection (Vero cell)Recombinant oncolytic herpes simplex virus type 1 (R130)第三代重组溶瘤病毒R130重组I型单纯疱疹病毒R130注射液（Vero细胞）

Targets

CD28 (Cluster of Differentiation 28)CD274 (Programmed cell death protein 1 ligand 1)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on recombinant type I herpes simplex virus R130 injection (Vero cells).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant type I herpes simplex virus R130 injection (Vero cells).

Explore the full profile